PHAT Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.

$18.16  -0.54 (-2.89%)
As of 12/03/2021 15:59:57 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/25/2019
Outstanding shares:  31,414,827
Average volume:  192,755
Market cap:   $587,457,265
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    71722W107
ISIN:        US71722W1071
Sedol:      BJLKVS6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   5.28
PS ratio:   0.00
Return on equity:   -156.34%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy